Abstract
Citation: Qiu TG (2014) Ocriplasmin and Muller Glia. Adv Ophthalmol Vis Syst 1(1): 00002. DOI: 10.15406/ aovs.2014.01.00002 Stalsmans et al. [1] published an article entitled of “Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes” based on the two pivotal Phase-III clinical safety and efficacy studies of ocriplasmin. The overall clinical efficacy was encouraging and marked 40%-60% anatomic closures of macular holes without further surgery. Whilst taking a close look at the safety profile noted on FDA Ophthalmic Drug Advisory Committee Meeting Debriefing [2], 5.6% patients experienced a vision decrease (2-3 line loss) during the first week post injection and slowly recovered over a six-month period, accordingly, a transit reduction of Electroretinogram (ERG) on both aand b-wave amplitudes was remarkable [2]. By far, there seems no sound biological explanation to such adverse event. This letter is to shed light on Muller glia as the primary biologic interface between ocriplasmin and neurosensory retina.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
